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AbstrACt
Objectives To describe (i) the trend in oral anticoagulant 
(OAC) use following the introduction of non-vitamin K 
antagonist oral anticoagulant (NOAC) therapy for stroke 
prevention in atrial fibrillation (AF) patients and (ii) the 
current patterns of use of NOAC therapy in new users with 
AF in France.
Design (i) Repeated cross-sectional study and (ii) 
population-based cohort study.
setting French national healthcare databases (50 million 
beneficiaries).
Participants (i) Patients with identified AF in 2011, 2013 
and 2016 and (ii) patients with AF initiating OAC therapy in 
2015–2016.
Primary and secondary outcome measures (i) Trend in 
OAC therapy use in patients with AF and (ii) patterns of use 
of NOAC therapy in new users with AF.
results Between 2011 and 2016, use of OAC therapy 
moderately increased (+16%), while use of antiplatelet 
therapy decreased (−22%) among all patients with 
identified AF. In 2016, among the 1.1 million AF patients, 
66% used OAC therapy and were more likely to be treated 
by vitamin K antagonist (VKA) than NOAC therapy, including 
patients at higher risk of stroke (63.5%), while 33% used 
antiplatelet therapy. Among 192 851 new users of OAC 
therapy in 2015–2016 with identified AF, NOAC therapy 
(66.3%) was initiated more frequently than VKA therapy, 
including in patients at higher risk of stroke (57.8%). 
Reduced doses were prescribed in 40% of NOAC new 
users. Several situations of inappropriate use at NOAC 
initiation were identified, including concomitant use of 
drugs increasing the risk of bleeding (one in three new 
users) and potential NOAC underdosing.
Conclusions OAC therapy use in patients with AF 
remains suboptimal 4 years after the introduction of 
NOACs for stroke prevention in France and improvement 
in appropriate prescribing regarding NOAC initiation is 
needed. However, NOAC therapy is now the preferred 
drug class for initiation of OAC therapy in patients with AF, 
including in patients at higher risk of stroke.
IntrODuCtIOn  
Non-vitamin K antagonist oral anticoagulants 
(NOACs) have been gradually introduced 
over the past decade as a more convenient, 
fixed-dose alternative to vitamin K antag-
onists (VKAs), the only oral anticoagulant 
(OAC) therapy available up until now for 
long-term stroke prevention in patients 
with non-valvular atrial fibrillation (AF).1 
Compared with VKA, NOAC therapy avoids 
the need for regular laboratory monitoring 
of patients by international normalised ratio 
(INR) testing due to a wider therapeutic 
window, allows once (rivaroxaban, edoxaban) 
or twice (dabigatran, apixaban) daily intake 
and is associated with fewer drug–drug inter-
actions to date.2–6 NOACs have been demon-
strated to have similar or superior efficacy to 
warfarin for stroke prevention in patients with 
strengths and limitations of this study
 ► This study is the first to report both the 2011–
2016 trend in oral anticoagulant (OAC) coverage 
in patients with atrial fibrillation (AF) following the 
introduction of non-vitamin K antagonist oral anti-
coagulant (NOAC) therapy in France and the current 
patterns of use of NOACs in new users including as-
sessment of potential inappropriate use.
 ► This study is based on reimbursement data for 
50 million beneficiaries with access to all OAC pre-
scriptions filled in the ambulatory setting.
 ► As indications for treatment are not available in the 
databases, AF was mostly identified on the basis of 
discharge and long-term disease diagnosis codes 
and an algorithm previously validated in the French 
healthcare databases that helped to further identify 
AF in outpatients.
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non-valvular AF, and these findings have recently been 
implemented in the 2016 European Society of Cardiology 
(ESC) guidelines that recommended NOAC over VKA 
therapy in this indication.7 Moreover, antiplatelet therapy 
is no longer recommended in these patients.7 8 The use 
of NOAC therapy, massively adopted worldwide including 
in France,9–15 is expected to overcome the suboptimal use 
of OAC therapy extensively reported with VKA therapy, 
including underprescribing and high discontinuation 
rates.16 17 
Despite their improved ease of use, NOAC prescribed 
dose needs to be adjusted to the patient’s clinical profile 
with regards to age, renal function, weight and risks of 
bleeding and drug–drug interactions. Two dose regimens 
are therefore proposed for each NOAC: standard dose 
regimen (ie, dabigatran 150 mg/12 hours, rivaroxaban 
20 mg/24 hours; apixaban 5 mg/12 hours) and reduced-
dose regimen (ie, dabigatran 75 mg or 110 mg/12 hours, 
rivaroxaban 10 mg or 15 mg/24 hours; apixaban 
2.5 mg/12 hours). The reasons for prescribing a reduced-
dose regimen are listed in the summary of product char-
acteristics (SmPCs) of each NOAC with differences across 
NOACs as well as in the ESC7 8 and European Heart 
Rhythm Association guidelines.18 Recent publications 
have suggested that the frequency of use of reduced-
dose NOACs in clinical practice could largely exceed that 
expected on the basis of the conditions summarised in 
these guidelines.11 19–21 However, national data are lacking 
concerning the current French patterns of NOAC use, 
including the potential issue of NOAC underdosing.
A steady increase in the initiation of NOAC therapy has 
already been reported in patients with AF in France,14 
but trends in OAC coverage of patients with AF following 
the introduction of NOACs and a description of the 
current national patterns of NOAC use have not yet been 
reported. This study, based on the French nationwide 
healthcare databases, therefore had a twofold objective: 
(1) to describe the trends in OAC use following the intro-
duction of NOAC for stroke prevention in patients with 
AF during the 2011–2016 period and (2) to describe the 
current patterns of use of OAC therapies with particular 
focus on NOAC use in new users with AF.
MethODs
Data source
French national health insurance (Assurance Maladie) 
covers the entire French population by means of several 
specific schemes according to the beneficiary’s occu-
pational sector, the largest scheme being the ‘Régime 
général’ (around 50 million beneficiaries).
This study was conducted using data from the French 
health insurance system database (Système national 
d'information inter-régimes de l'Assurance maladie, 
SNIIRAM) linked to the French hospital discharge data-
base (Programme de médicalisation des systèmes d'in-
formation, PMSI).22 23 The SNIIRAM database contains 
individualised, anonymous and comprehensive data on 
health spending reimbursements. Demographic data 
include date of birth, gender and vital status. Drugs are 
coded according to the Anatomical Therapeutic Chem-
ical (ATC) classification. Each packaging of each product 
is identified by means of a national-specific pack iden-
tifier code providing information on the name of the 
product, active ingredient and dose per unit, number 
of units and route of administration; but, the exact 
dosage prescribed and the indication are not avail-
able. However, for most drugs, particularly OACs, each 
dispensing of the prescribed drug cannot exceed the 
quantity necessary for 1 month of treatment. The PMSI 
database provides detailed information about discharge 
diagnoses and medical procedures related to all hospital-
isations in France. This information regarding morbidi-
ties is completed by diagnoses corresponding to patient 
eligibility for 100% reimbursement of severe and costly 
long-term diseases (LTD) and disability, such as AF, coro-
nary heart disease, certain debilitating diseases (such as 
multiple sclerosis or rheumatoid arthritis), HIV infection, 
cancer, etc. All information concerning medical diagnosis 
is encoded according to the International Classification 
of Diseases, 10th revision (ICD-10). Finally, the SNII-
RAM-PMSI databases also indicate medical procedures 
performed in the ambulatory setting, including infor-
mation about the type and date of all laboratory tests 
performed, but not including their results.
The French healthcare databases have been previously 
described and used in epidemiological and pharmacoep-
idemiological studies.22 24–26
study populations and study designs
Two study populations were defined; one for each 
objective.
To answer the first objective, a repeated cross-sectional 
study was performed to describe the trends in OAC use 
following the introduction of NOAC in patients with AF. 
Patients with AF were identified in 2011 (as none of the 
NOACs was available for stroke prevention in France) and 
2016 (the most recent data available at the time of writing 
the study protocol; dabigatran, rivaroxaban and apixaban 
were all reimbursed for stroke prevention in France, as 
apixaban was reimbursed from January 2014 onwards). 
OAC coverage was also calculated for year 2013 as this 
year represented the first calendar year for which the first 
two NOACs were available in France, that is a pivotal year 
for the pharmacological management of AF by OACs. For 
each of these calendar years, a patient was considered to 
have AF when at least one diagnosis of AF (ICD-10 code 
I48) was identified from discharge and LTD diagnoses in 
the SNIIRAM-PMSI database in the calendar year consid-
ered or during the previous 5 years. Patients with no 
continuous ‘Régime général’ health insurance coverage 
for at least 6 years before the calendar year considered 
were excluded.
To answer the second objective, a population-based 
cohort study was performed including patients with AF 
initiating OAC therapy in 2015–2016. First, OAC new 









pen: first published as 10.1136/bm





3Maura G, et al. BMJ Open 2019;9:e026645. doi:10.1136/bmjopen-2018-026645
Open access
users were identified among patients with continuous 
‘Régime général’ health insurance coverage as those with 
at least one reimbursement for OAC therapy in 2015–2016 
and no reimbursement for any OAC (VKA or NOAC) in 
the previous 24 months. The patient’s index date was the 
date of first OAC reimbursement identified during the 
2015–2016 period. Second, the cohort of NOAC news 
users was restricted to those treated for AF: (i) patients 
treated for other OAC indications that is, patients treated 
for deep vein thrombosis/pulmonary embolism (DVT/
PE) or with lower limb orthopaedic procedures were 
excluded; (ii) OAC new users treated for AF were iden-
tified from the resulting cohort as the sum of ‘OAC new 
users with confirmed AF’ for those with a diagnosis of 
AF (ICD-10 code I48) or specific AF management proce-
dures identified from LTD or hospitalisation discharge 
data during a 6-year preindex period, and ‘OAC new 
users with probable AF’ for outpatients identified using 
an algorithm discriminating AF from DVT/PE with 95% 
specificity.27 The remaining patients were not classified as 
probable patients with AF and were excluded. Codes used 
for identification of AF and all of the patient characteris-
tics considered, including comorbidities, are displayed in 
online supplementary table 1.
Patient and public involvement
Patients and or public were not involved.
exposure
NOAC (dabigatran, rivaroxaban and apixaban) and VKA 
therapies (fluindione, warfarin and acenocoumarol) 
were identified using ATC codes; edoxaban was not avail-
able in France during the period considered.
Outcomes
Trends in OAC therapy use in patients with AF
The proportion of patients with AF treated by OAC 
therapy was assessed before and after approval of NOAC 
therapies for stroke prevention in France. Trends in the 
use of antiplatelet agents were also assessed in patients 
with AF over the same timeframe.
Patterns of use of NOAC therapy in new users with AF
The description of patterns of NOAC use in new users 
treated for AF in 2015–2016 included comparison of the 
baseline characteristics among NOAC new users and 
compared with those of VKA new users and potential 
inappropriate use of NOAC therapy was then investigated 
by identifying:
(i) NOAC off-label use or non-approved indication/
dose: contraindications to NOAC therapy according to 
SmPCs (concomitant coagulopathy, purpura and other 
haemorrhagic conditions, liver fibrosis and cirrhosis, 
recent gastrointestinal ulceration or intracranial haem-
orrhage), valvular AF (NOAC are only approved for 
non-valvular AF), prosthetic heart valve (contraindicated 
for dabigatran), cancer (NOAC are not approved for 
prevention of thromboembolism in patients with cancer) 
and prescription of NOAC doses not approved for stroke 
prevention in Europe (dabigatran 75 mg and rivaroxaban 
10 mg are not approved for stroke prevention in Europe 
and are therefore off-label doses in patients with AF); (ii) 
non-compliance with guidelines with respect to follow-up 
and clinical work-up of patients during the first year 
following NOAC initiation: no monitoring of patients’ 
renal function (renal function should be assessed at initi-
ation and annually during NOAC therapy),28 discontinu-
ation of NOAC therapy (OAC therapy is recommended as 
lifetime treatment in most patients with AF); (iii) clinically 
relevant drug–drug interactions at initiation increasing 
the bleeding risk at initiation and (iv) potential inappro-
priate underdosing, that is, patients in whom the NOAC 
dose prescribed at initiation was inappropriately reduced 
in view of their individual stroke and bleeding risks.
Data analysis
Descriptive analyses are expressed as mean and SD for 
continuous variables, and numbers and percentages for 
categorical variables.
Trends in OAC therapy use in patients with AF
For each calendar year, the proportion of patients treated 
by a drug was defined by the number of patients with at 
least one reimbursement for this drug in the calendar year 
considered over the total number of patients identified 
as having AF in the same year. Proportions are reported 
according to the type of OAC first reimbursed in the year 
considered. Antiplatelet drugs and OAC therapies were 
considered to be coprescribed when they were reim-
bursed at least once on the same day during the calendar 
year studied. Analyses were replicated in subgroups of 
patients with AF: (i) aged 75 years and over; (ii) female 
and male, separately; (iii) with a history of hospitalisation 
for arterial thromboembolic events (ATE) and (iv) with 
concomitant ischaemic heart disease or prosthetic heart 
valve.
Patterns of use of NOAC therapy in new users with AF
Baseline characteristics of NOAC new users with AF 
included sociodemographic data, including deprivation 
index of the patient’s municipality of residence,29 type 
of initial prescriber, clinical scores predicting the risk of 
stroke (CHA2DS2-VASc score) or bleeding (HAS-BLED 
score),30 31 adapted to claims data and the other main 
comorbidities and comedications, including proxies of 
frailty. A negative binomial regression analysis for each 
NOAC therapy and each baseline characteristic was 
performed to assess the association between these char-
acteristics and the choice of NOAC therapy versus VKA 
therapy, while adjusting for age and sex.
Compliance with guidelines regarding renal function 
monitoring and treatment persistence patterns were 
assessed in new users for whom data for at least 1 year 
of follow-up were available, that is, patients included in 
2015 and who had not died and had not been hospital-
ised for 3 months or longer. Compliance with renal func-
tion monitoring was assessed at NOAC initiation (no 
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reimbursement for renal function monitoring during 
the 3 months before and the 3 months after NOAC initi-
ation) and during the first year following treatment initi-
ation. OAC non-persistence patterns were assessed over 
the 1-year period following the index date by calculating 
proxies of OAC discontinuation: number of patients with 
only one reimbursement and 1-year crude discontinua-
tion rates.
Drugs increasing the risk of bleeding were those respon-
sible for clinically relevant pharmacodynamic interactions 
with OAC therapy, that is, concomitant reimbursement of 
other parenteral and oral antithrombotic drugs, non-ste-
roidal anti-inflammatory drugs; selective serotonin 
reuptake inhibitors and selective serotonin-norepineph-
rine reuptake inhibitors.7 18 32 Patients taking concomi-
tant drugs with OAC therapy were defined as those with 
a reimbursement for the drug of interest during the 
period corresponding to the index date and the following 
45 days. Analyses were replicated in VKA new users for 
descriptive purposes.
Finally, potential inappropriate underdosing with 
NOACs was defined as initiation of NOAC therapy in 
patients at risk of stroke in whom reduced doses of NOAC 
were prescribed with no identified justification. As this 
study was based on claims data and as, up until 2016, 
ESC guidelines recommended prescribing reduced-dose 
NOAC in patients with HAS-BLED ≥3,8 the proportion 
of AF patients initiating reduced-dose NOAC with an 
HAS-BLED score <3 among all NOAC new users with a 
CHA2DS2-VASc score ≥2 was used to quantify potential 
inappropriate underdosing in NOAC new users. Anal-
yses were replicated in patients (i) with CHA2DS2-VASc 
score ≥4 and (ii) aged 75 and over with a history of ATE.
results
trends in OAC therapy use in patients with AF
The number of patients identified from French health-
care databases as having AF increased between 2011 
(n=853 440) and 2016 (n=1 098 657). A high propor-
tion of these patients were identified exclusively by 
hospitalisation discharge diagnosis and this proportion 
decreased only slightly over this time interval from 90.2% 
(n=770 002) to 86.2% (n=946 657).
Between 2011 and 2016, the proportion of patients 
with at least one reimbursement for OAC therapy among 
all patients with AF moderately increased (+16%) from 
56.7% to 65.8%, corresponding to a steady decrease in 
VKA use (from 56.6% to 40.8% of all patients with AF) 
associated with the introduction of NOACs (from 0.6% to 
27.7%). In 2016, among patients with identified AF, VKA 
therapy remained the preferred OAC therapy (62.0%), 
Figure 1 Time trends in the use of oral antithrombotic therapy between 2011 and 2016 in patients with AF in France. (A) Total 
population: patients with AF. (B) Patients aged 75 years and over. (C) Female patients (solid line) and male patients (dashed 
line). (D) Patients with history of arterial thrombo-embolicevents. (E) Patients with IHD or with prosthetic heart valve. For Figures 
B, D and E, estimates from all AF patients already presented in figure A. are indicated by dashed lines for the purposes of 
comparison. AF, atrial fibrillation; IHD, ischaemic heart diseases; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral 
anticoagulant; VKA, vitamin K antagonist.
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including in patients aged 75 years and over (67.0%) and 
in those with a history of ATE (63.5%).
Between 2011 and 2016, the use of antiplatelet therapy 
decreased in patients with AF (−22%), but the propor-
tion of patients with concomitant OAC and antiplatelet 
therapy remained stable (9.7% in 2016). In 2016, 32.5% 
of patients with AF had at least one reimbursement for 
antiplatelet therapy during the year.
Similar trends were observed in the subgroup anal-
yses. A slightly higher rate of OAC therapy was observed 
in patients with a history of ATE (68.4% vs 65.8% in the 
total cohort in 2016). However, OAC coverage was lower 
in women than in men with AF (64.7% vs 66.8% in 2016) 
(figure 1).
Patterns of use of nOAC therapy in new users with AF
Baseline characteristics of OAC new users
Among 540 914 patients initiating OAC therapy in 
2015–2016, a total of 192 851 (35.7%) patients were 
included in the study population, corresponding to 
127 841 NOAC new users and 65 010 VKA new users 
with AF. The mains reasons for ineligibility were other 
indications or uncertain identification of the indication 
for NOAC (figure 2).
The mean age of the NOAC new users cohort was 
74.1±11.6 years; patients over the age of 80 represented 
37.3% of the total cohort. One-half of the NOAC new 
users were women, and 40.0% received a reduced dose 
at initiation (62.2% for dabigatran new users). Apix-
aban was the NOAC most commonly initiated; apix-
aban new users were older and had more comorbidities 
than the other two groups of NOAC new users. NOAC 
therapy was more likely to be initiated than VKA therapy 
among patients aged 75 years and older (59.4%) and in 
patients with a history of ATE (57.8%) (table 1).
Characteristics associated with bleeding risk, such 
as older age, renal impairment, history of bleeding or 
bleeding predisposition and treatment with a concomi-
tant drug increasing the risk of bleeding at OAC initia-
tion, were strong predictors of being treated with VKA 
therapy versus NOAC therapies (online supplementary 
table 2).
Potential inappropriate use of NOAC therapy
About 15% of NOAC new users with AF were considered 
to be using NOAC off-label or for a non-approved indica-
tion. In particular, 8.5% of NOAC new users with AF had 
valvular heart disease (8.5%), including prosthetic heart 
valve (1.5%) and 4.6% had a recently or currently treated 
cancer (table 2).
About 15% and 9% of NOAC new users had no reim-
bursement for renal function tests at initiation and during 
the 1-year period postinitiation, respectively. Discontin-
uation during the 1-year period following initiation was 
frequent, as more than 20% of patients had five or less 
reimbursements (table 2).
Nearly 30% of NOAC new users were using at least one 
concomitant drug increasing the risk of bleeding (52% in 
VKA new users). The most common concomitant drugs 
concerned at initiation were antiplatelet agents or paren-
teral anticoagulants (table 2).
Among the 116 391 NOAC new users with AF with 
a CHA2DS2-VASc score ≥2, 29.1% (n=33 845) were 
prescribed a reduced dose although they had an 
HAS-BLED score <3. This meant that nearly 1 in 3 
NOAC new users with AF and at risk of stroke were there-
fore potentially prescribed an inappropriately reduced 
dose of NOAC at initiation. This proportion was 33% 
(n=24 281) and 14.5% when defining patients at risk 
of stroke as patients with a CHA2DS2-VASc score ≥4 and 
aged 75 and over with a history of ATE, respectively 
(figure 3).
Differences in baseline characteristics were observed 
in patients with HAS-BLED <3 according to the type 
of NOAC dose prescribed, for example, patients with 
reduced-dose NOAC were older and frailer than those 
Figure 2 Patient flow chart. AF, atrial fibrillation; DVT/
PE, deep vein thrombosis/pulmonary embolism;  NOAC, 
non-vitamin K antagonist oral anticoagulant; OAC, oral 
anticoagulant; VKA, vitamin K antagonist.
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NOAC: reduced doses 5652 (62.2) 19 429 (35.7) 26 003 (40.4) 51 084 (40.0) NA
Female sex 4546 (50.0) 26 147 (48.0) 33 375 (51.9) 64 068 (50.1) 33 865 (52.1)
Age (years), mean (SD) 74.1 (11.6) 72.8 (11.9) 75.3 (11.3) 74.1 (11.6) 78.0 (11.3)
  18–54 548 (6.0) 4007 (7.4) 3172 (4.9) 7727 (6.0) 2361 (3.6)
  55–64 1117 (12.3) 7651 (14.0) 7117 (11.1) 15 885 (12.4) 5680 (8.7)
  65–74 2514 (27.7) 16 057 (29.5) 16 645 (25.9) 35 216 (27.5) 12 969 (19.9)
  75–79 1554 (17.1) 9053 (16.6) 10 692 (16.6) 21 299 (16.7) 9587 (14.7)
  ≥80 3352 (36.9) 17 688 (32.5) 26 674 (41.5) 47 714 (37.3) 34 413 (52.9)
  ≥90 493 (5.4) 2559 (4.7) 4654 (7.2) 7706 (6.0) 8399 (12.9)
Deprivation index
  Quintile 1 (least deprived) 1394 (15.3) 10 265 (18.9) 11 266 (17.5) 22 925 (17.9) 10 263 (15.8)
  Quintile 2 1586 (17.5) 10 678 (19.6) 12 496 (19.4) 24 760 (19.4) 11 884 (18.3)
  Quintile 3 1780 (19.6) 10 701 (19.7) 12 799 (19.9) 25 280 (19.8) 12 811 (19.7)
  Quintile 4 1917 (21.1) 10 794 (19.8) 13 142 (20.4) 25 853 (20.2) 14 272 (22.0)
  Quintile 5 (most deprived) 2113 (23.3) 11 172 (20.5) 13 825 (21.5) 27 110 (21.2) 14 699 (22.6)
  Overseas departments 295 (3.2) 846 (1.6) 772 (1.2) 1913 (1.5) 1081 (1.7)
First prescriber’s specialty
  Hospital practitioner 3720 (40.9) 22 905 (42.1) 29 316 (45.6) 55 941 (43.8) 39 083 (60.1)
  General practitioner 2062 (22.7) 11 145 (20.5) 11 590 (18.0) 24 797 (19.4) 15 539 (23.9)
  Private cardiologist 3093 (34.0) 18 978 (34.9) 21 843 (34.0) 43 914 (34.4) 8511 (13.1)
  Private orthopaedic surgeon 16 (0.2) 100 (0.2) 95 (0.1) 211 (0.2) 73 (0.1)
  Other private specialist 168 (1.8) 1149 (2.1) 1276 (2.0) 2593 (2.0) 1583 (2.4)
CHA2DS2-VASc score†
  Mean score (SD) 3.7 (1.6) 3.5 (1.6) 3.9 (1.6) 3.7 (1.6) 4.5 (1.6)
  0 183 (2.0) 1294 (2.4) 847 (1.3) 2324 (1.8) 309 (0.5)
  1 635 (7.0) 4854 (8.9) 3637 (5.7) 9126 (7.1) 1607 (2.5)
  ≥2 8267 (91.0) 48 308 (88.7) 59 816 (93.0) 1 16 391 (90.1) 63 094 (97.0)
  C (heart failure) 2849 (31.4) 17 805 (32.7) 23 548 (36.6) 44 202 (34.6) 32 727 (50.3)
  H (antihypertensive drugs) 7547 (83.1) 44 260 (81.3) 54 596 (84.9) 106 403 (83.2) 59 139 (91.0)
  D(iabetes) 1959 (21.6) 11 279 (20.7) 14 087 (21.9) 27 325 (21.4) 18 806 (28.9)
  S(troke: ATE) 1207 (13.3) 4930 (9.1) 8448 (13.1) 14 585 (11.4) 10 638 (16.4)
  V(ascular diseases) 2242 (24.7) 13 924 (25.6) 18 766 (29.2) 34 932 (27.3) 28 894 (44.4)
Age ≥75 and arterial thromboembolic 
events†
769 (8.5) 3126 (5.7) 5608 (8.7) 9503 (7.4) 7762 (11.9)
Age <65 and no arterial 
thromboembolic events† 
1510 (16.6) 11 074 (20.3) 9396 (14.6) 21 980 (17.2) 7035 (10.8)
HAS-BLED score†
  Mean score (SD) 2.0 (0.9) 1.9 (0.9) 2.1 (0.9) 2.0 (0.9) 2.7 (1.0)
  ≥3 2169 (23.9) 11 388 (20.9) 16 834 (26.2) 30 391 (23.8) 36 417 (56.0)
  A(bnormal)
   Renal function 345 (3.8) 2426 (4.5) 3822 (5.9) 6593 (5.2) 14 260 (21.9)
   Liver function 169 (1.9) 967 (1.8) 1106 (1.7) 2242 (1.8) 2372 (3.6)
  B(leeding)
   Predisposition 182 (2.0) 1161 (2.1) 1605 (2.5) 2948 (2.3) 5873 (9.0)
   Major bleeding 692 (7.6) 3729 (6.8) 5134 (8) 9555 (7.5) 9348 (14.4)
Continued
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OAC therapy use among patients with AF improved in 
France between 2011 and 2016, but remained suboptimal 
with about 66% of the 1.1 million patients with identified 
AF treated by OAC therapy in 2016. Use of antiplatelet 
therapy in patients with AF decreased over the same 
period, but still concerned 33% of all patients with AF in 
2016. Patients with AF were more likely to be treated by 
VKA than NOAC therapy, including older patients and 
those at higher risk of stroke.
Nearly 193 000 patients with AF were identified as OAC 
new users in 2015–2016: patients were more likely to be 
treated by NOAC than VKA therapy, including older 
patients and those at higher risk of stroke. Results on 
current patterns of use of NOAC therapy in new users 
with AF suggest several situations of inappropriate use, 
including frequent concomitant use of drugs increasing 
the risk of bleeding and potential inappropriate 
underdosing.
Comparison with postmarketing literature and clinical 
implications
The overall improvement of management of patients 
with AF observed with regards to OAC therapy after 
the introduction of NOACs has been reported in many 
countries.33–36 The same applies to the steady decrease 
in VKA use in favour of NOAC therapies,12 37 38 and the 
gaps remaining in optimal OAC coverage and high anti-
platelet drug use.39–41
This study demonstrated channelling of NOAC therapy 
towards patients at lower risk of stroke and bleeding when 
considering all patients with AF, in line with what has 
become a common feature reported worldwide in clin-
ical practice by many observational studies on the current 
patterns of use of NOACs.15 42–45 In particular, data 
from the ESC-sponsored ‘EURObservational Research 
Programme on AF’ General Long-Term Registry showed 













   Alcohol abuse‡ 272 (3.0) 1698 (3.1) 1730 (2.7) 3700 (2.9) 2923 (4.5)
   Drug–drug interactions 947 (10.4) 5838 (10.7) 7570 (11.8) 14 355 (11.2) 23 451 (36.1)
    Parenteral anticoagulant 
(heparin)
64 (0.7) 331 (0.6) 361 (0.6) 756 (0.6) 9824 (15.1)
    Antiplatelet drugs 826 (9.1) 5225 (9.6) 6951 (10.8) 13 002 (10.2) 15 433 (23.7)
    NSAIDs 72 (0.8) 365 (0.7) 344 (0.5) 781 (0.6) 212 (0.3)
Other comorbidities† 
  Ischaemic heart disease 1821 (20.0) 11 321 (20.8) 15 439 (24.0) 28 581 (22.4) 23 657 (36.4)
  Frailty (proxies) 1666 (18.3) 8971 (16.5) 12 730 (19.8) 23 367 (18.3) 24 175 (37.2)
  Dementia or Parkinson’s disease 524 (5.8) 3204 (5.9) 4125 (6.4) 7853 (6.1) 7437 (11.4)
  Psychiatric disorders 1722 (19.0) 10 593 (19.5) 12 844 (20.0) 25 159 (19.7) 16 598 (25.5)
  Smoking‡ 1024 (11.3) 6481 (11.9) 7442 (11.6) 14 947 (11.7) 11 434 (17.6)
Comedications§
  Antiarrhythmics or cardiac glycosides 5996 (66.0) 35 761 (65.7) 41 031 (63.8) 82 788 (64.8) 35 600 (54.8)
  Lipid-lowering agents 3913 (43.1) 22 250 (40.9) 28 812 (44.8) 54 975 (43.0) 31 903 (49.1)
  Oral corticosteroids 1105 (12.2) 6964 (12.8) 8079 (12.6) 16 148 (12.6) 8967 (13.8)
  Antiulcer agents 4295 (47.3) 24 842 (45.6) 31 469 (48.9) 60 606 (47.4) 39 842 (61.3)
  Polymedication (≥5 ATC classes) 3750 (41.3) 21 725 (39.9) 28 196 (43.9) 53 671 (42.0) 45 153 (69.5)
  Polymedication (≥10 ATC classes) 738 (8.1) 4653 (8.5) 6246 (9.7) 11 637 (9.1) 14 947 (23.0)
*Unless otherwise stated.
†Comorbidities were defined using a rolling 1-year period following the initiation of OAC therapy.
‡Smoking or alcohol data: measured by using proxies such as reimbursements for specific therapy or hospitalisations related to smoking or 
alcohol consumption/diseases.
§Comorbidities were defined using a rolling 4-month period preceding the initiation of OAC therapy.
ATC, Anatomical Therapeutic Chemical classification; ATE, arterial thromboembolic events (ischaemic stroke, arterial systemic embolism or 
transient ischaemic attack); NOAC, non-vitamin K antagonist oral anticoagulant; NSAIDs, non-steroidal anti-inflammatory drugs; VKA, vitamin 
K antagonist.
Table 1 Continued 
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non-valvular heart diseases were also found to be clinical 
predictors for being treated with NOACs versus VKAs.46
However, NOAC therapy is now the preferred OAC 
therapy at initiation in the oldest patients and those at 
higher risk of stroke. This French pattern of OAC use 
has never been previously reported and contrasts with 
published results concerning earlier periods.47 This 
emerging pattern is encouraging for AF management, as 
older and high-risk patients are those who should derive 
most benefit from NOAC versus VKA therapy.48
Reduced doses were often prescribed in OAC new 
users, including dabigatran 75 mg and rivaroxaban 
10 mg, which are not approved for stroke prevention 
in Europe.49 In addition to the overall channelling 
mentioned above, these findings may reflect a ‘bleeding 
avoidance’ strategy of prescribers (ie, overestimation of 
the potential bleeding risk versus the likely benefit of 
stroke reduction) and the differential perception of the 
comparative safety of NOACs versus VKA and between 
NOACs. The early safety alert on bleeding in dabiga-
tran-treated patients, followed by the contraindication of 
this NOAC in patients with prosthetic heart valves, may 
have reinforced the fears of prescribers in relation to the 
safety of dabigatran, which would explain the difference 
in reduced-dose prescription rates between the three 
NOACs in this study, despite the intermediate stroke and 
Table 2 Potential inappropriate use of NOAC therapy in oral anticoagulant-naïve patients with AF in 2015–2016











n=1 27 841 
Contraindications or non-approved indication/dose 1457 (16.0) 8614 (15.8) 9542 (14.8) 19 613 (15.3) NA
Any valvular heart disease 649 (7.1) 4146 (7.6) 6122 (9.5) 10 917 (8.5) 16 461 (25.3)
  Prosthetic heart valve (mechanical or bioprosthetic valves) 106 (1.2) 665 (1.2) 1096 (1.7) 1867 (1.5) 6726 (10.3)
Recently hospitalised for coagulopathy, purpura and other 
haemorrhagic conditions*
90 (1.0) 479 (0.9) 596 (0.9) 1165 (0.9) 2142 (3.3)
Liver fibrosis and cirrhosis* 50 (0.6) 282 (0.5) 367 (0.6) 699 (0.5) 1174 (1.8)
Recent gastrointestinal ulceration or intracranial haemorrhage† 40 (0.4) 120 (0.2) 248 (0.4) 408 (0.3) 350 (0.5)
Recently or currently treated cancer* 417 (4.6) 2531 (4.6) 2898 (4.5) 5846 (4.6) 4252 (6.5)
Reduced-dose NOAC not approved for stroke prevention in 
patients with AF in Europe
357 (3.9) 1844 (3.4) NA 2201 (3.5) NA
Inappropriate use during follow-up‡
No monitoring of renal function at initiation 637 (16.8) 3804 (15.5) 3642 (14.5) 8083 (15.1) 5401 (17.0)
No monitoring of renal function in the year postinitiation 378 (10.0) 2347 (9.6) 2138 (8.5) 4863 (9.1) 2984 (9.4)
Non-persistence patterns, N (%)
  One reimbursement only 605 (15.9) 2666 (10.9) 1771 (7.1) 5042 (9.4) 2426 (7.6)
  One-year treatment discontinuation rates§ 984 (25.9) 6210 (25.4) 4524 (18,0) 11 718 (21,9) 8399 (26.4)
Concomitant use of drug increasing the risk of bleeding¶ 2639 (29.3) 15 797 (29.3) 18 556 (29.2) 36 992 (29.3) 33 025 (52.3)
Antiplatelet agents or parenteral anticoagulants 1728 (19.2) 10 386 (19.3) 12 382 (19.5) 24 496 (19.4) 28 112 (44.5)
  Parenteral anticoagulants 287 (3.2) 1577 (2.9) 1520 (2.4) 3384 (2.7) 12 078 (19.1)
  Antiplatelet agents 1490 (16.6) 9179 (17.0) 11 170 (17.6) 21 839 (17.3) 19 710 (31.2)
   Aspirin 1336 (14.8) 8215 (15.2) 10 026 (15.8) 19 577 (15.5) 17 770 (28.1)
NSAIDs 375 (4.2) 2111 (3.9) 2017 (3.2) 4503 (3.6) 1030 (1.6)
SSRIs and SSNRIs 836 (9.3) 4852 (9.0) 5880 (9.2) 11 568 (9.1) 7317 (11.6)
*Comorbidities identified using hospitalisation and/or LTD data, and/or specific procedures during a rolling 1-year period preceding the 
initiation of OAC therapy.
†Comorbidities identified using hospitalisation data during a rolling 6-week period preceding the initiation of OAC therapy.
‡Data on patients with at least a 1 year of follow-up ie, patients initiating OAC in 2015 after excluding patients who died and those 
hospitalised for 3 months or longer (n=3796; 24 483; 25 118; 53 397 and 31 777 for dabigatran, rivaroxaban, apixaban, total NOAC and total 
VKA new users, respectively); period considered (unless otherwise stated): rolling 1-year period following the initiation of OAC therapy (index 
date included).
§1-year crude discontinuation rate for patients initiating OAC in 2015 who died and those hospitalised for 3 months or longer, defined as 
prolonged treatment discontinuation ie, 90-day gap with no medication coverage after the 30-day coverage period of a refill.
¶Data for new users still alive after a 45-day period following the index date (n=9001; 53 885; 63 578; 126 464 and 63 180 for dabigatran, 
rivaroxaban, apixaban, total NOAC and total VKA new users, respectively); period considered: rolling 6-week period following the initiation of 
OAC therapy (index date included).
AF, atrial fibrillation; ATE, arterial thromboembolic events; NA, not applicable; NOAC, non-vitamin K antagonist oral anticoagulant; NSAIDs, 
non-steroidal anti-inflammatory drugs; SSNRIs, selective serotonin-norepinephrine reuptake inhibitors; SSRIs, selective serotonin reuptake 
inhibitors; VKA, vitamin K antagonist.
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bleeding risk profile of dabigatran compared with that of 
rivaroxaban and apixaban in new users. Similarly, among 
NOAC new users, apixaban was prescribed to the oldest 
and most severe patients. Apixaban was the only NOAC 
found to be superior to warfarin for all types of bleeding 
outcome and all-cause mortality, which would also illus-
trate the tendency of physicians to prescribe OAC thera-
pies according to bleeding risk.5 This may also explain the 
potential inappropriate underdosing observed in NOAC 
users in this study. This pattern of NOAC use has been 
previously reported, but mostly in field and registry studies 
based on small sample sizes. The reported inappropriate 
underdosing rate varies according to studies and the defi-
nition used. NOAC underdosing concerned 30.4% of 
Turkish patients in the RAMSES study (n=2086),50 18.4% 
of Japanese patients of the KiCS AF registry (n=1284),51 52 
between 19.7% and 27.6% of patients in the SAKURA AF 
registry (n=3266)53 and 9.4% to 16% of patients in the 
ORBIT-AF II registry (n=7925).21 54 In the subgroup of 
Dutch patients (n=899) enrolled in the XANTUS registry, 
33% of patients were also treated with reduced-dose rivar-
oxaban despite presenting normal renal function.55 Using 
a large US administrative database, Yao et al found that 
13.3% of the 13 392 NOAC new users with no renal indi-
cation for dose reduction were potentially underdosed.56 
Taken together with our results, these data suggest that 
inappropriate underdosing might be a common issue in 
NOAC new users that should be systematically assessed 
when studying NOAC patterns of use. This is of partic-
ular concern, as recent data have suggested a relationship 
between NOAC dose and clinical outcomes.57 In partic-
ular, NOAC underdosing has been shown to be associated 
with increased risk for adverse outcomes.21 56
These patterns of NOAC use contrast with the other 
patterns concomitantly observed in this study, such as 
the high level of concomitant prescription of antiplatelet 
agents and parenteral anticoagulants or, to a lesser 
extent, NOAC use in non-approved indications such as 
prosthetic heart valves that are both associated with an 
increased risk of bleeding.58–60
strengths and limitations
This study is the first to report the improved trend in OAC 
coverage in French patients with AF over the last 5 years 
as well as the recent patterns of use of OAC therapy in 
new users, particularly including a nationwide assess-
ment of the growing issue of NOAC underdosing, based 
on health data for more than 50 million beneficiaries. 
Moreover, all OAC prescriptions filled in the ambulatory 
setting are captured in the databases and are reimbursed 
with no restriction of coverage: selection bias related to 
the access of patients to more expensive NOAC therapy is 
therefore not an issue with the use of French healthcare 
databases.22 61
However, several limitations related to the nature of 
the data used should be underlined. First of all, it cannot 
be verified whether patients actually took the drugs for 
which they were reimbursed. Second, as the indication 
for treatment is not available in the databases, and despite 
the use of an algorithm to identify AF among outpatients 
in the French healthcare databases, identification of AF 
was mostly based on non-validated discharge and LTD 
diagnoses recorded in the databases. Moreover, it cannot 
be excluded that the increase in the identified number 
of patients with AF over the 2011–2016 period could be 
partially explained by changes in LTD legislation in 2011 
(eg, hypertension was removed from the list of LTD, 
while access to LTD was facilitated for patients with severe 
arrhythmia and valvular heart diseases) which could have 
helped to identify patients with AF. Third, identification 
of inappropriate underdosing at NOAC initiation was 
also indirectly assessed by using stroke and bleeding risk 
scores computed from claims data. Important medical 
data such as patient’s weight, glomerular filtration rate 
and exact alcohol consumption are not available in the 
French healthcare databases, which may have led to 
underestimation of the HAS-BLED score and therefore 
to overestimation of the proportion of patients poten-
tially underdosed at initiation. These missing clinical data 
may also explain the prescription of reduced-dose NOAC 
at treatment initiation in clinical practice. Furthermore, 
the agreement between these empirical scores in patients 
with AF and the prescriber-assessed stroke and bleeding 
risk is a subject of discussion.62 Consequently, the rate 
of inappropriate underdosing should be interpreted 
with caution and must be confirmed by further studies. 
However, NOAC misuse and underdosing have also been 
reported in a French prospective field study based on 
patients’ medical charts.63 Of note, as INR values were not 
available in the databases, underdosing with VKA therapy 
was not assessed in this study, but has been frequently 
reported and must not be overlooked.53 64 In addition, as 
stated in the 2016 ESC guidelines,7 HAS-BLED score is 
not designed to evaluate prescription of NOAC type and 
Figure 3 Potential NOAC underdosing in new users with AF. 
NOAC, non-vitamin K antagonist oral anticoagulant; AF, atrial 
fibrillation; ATE,  arterial thromboembolic events.
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dosage, and no longer must be used for this purpose in 
clinical practice.
Finally, the results for NOAC and VKA new users are 
difficult to compare, as they were not adjusted for signif-
icant differences in baseline characteristics, and this 
comparison was not the purpose of this study.
COnClusIOn
OAC therapy use has modestly increased after the intro-
duction of the NOACs for stroke prevention in patients 
with AF in France, and NOAC therapy is now the preferred 
OAC therapy at initiation in older patients at higher risk 
of stroke. However, results from this nationwide drug util-
isation study suggest the need for improvement in appro-
priate prescription of OAC therapy in these patients, 
especially regarding the use of concomitant interacting 
drugs and the choice of initial NOAC dose.
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